Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Next >>

Post by Viking2233on Apr 03, 2024 9:10am

240 Views

Post# 35967233

More Great News

Arch is on a roll snd just keeps pumping out more great news. We get another Canadian site, and it just happens to be the #1 Heart Hospital in Canada and top 10 in the world.

We now have 8 sites on board with one more to be announced for Canada.

You can bet that several sites in the USA have taken notice and it will only be a matter of time before they announce the first site in the USA!

The more sites we have the faster we dose patients. The fact more sites continue to participate in the trial suggest that trial is going well. The more we dose the more we reduce the risk.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec